---
run_id: RUN_FIRST_LIVE_IDI01_XHIGH_FOUNDATION
corpus_id: WHALE_HUNT
transcript_id: IDI01
stage_id: 1.3.2
stage_name: kt_problem_analysis
branch_id: IDI01.CONC001
prompt_version: "1.0.0"
schema_version: "1.0.0"
model: gpt-5.5
model_profile: strongest_reasoning
input_artifacts:
  - /Users/ericeskey/Documents/Codex/runs/RUN_FIRST_LIVE_IDI01_XHIGH_FOUNDATION/outputs/IDI01/1.0_observation_atoms.md
  - /Users/ericeskey/Documents/Codex/runs/RUN_FIRST_LIVE_IDI01_XHIGH_FOUNDATION/outputs/IDI01/1.3.1_kt_situation_appraisal.md
created_at: 2026-07-01T14:24:53-07:00
---

```yaml
problem_analysis:
  id: "IDI01.KTP001"
  local_id: "KTP001"
  transcript_id: "IDI01"
  corpus_id: "WHALE_HUNT"
  run_id: "RUN_FIRST_LIVE_IDI01_XHIGH_FOUNDATION"
  selected_concern_id: "IDI01.CONC001"
  problem_statement: "Cell therapy processing demand is increasing, and lab/BSC-based processing workflows are expected not to keep up."
  deviation_statement: "Unknown quantified standard; actual evidence shows increasing requests and more commercial therapies while Catherine says doing everything in a lab with biological safety cabinets is not gonna be able to keep up."
  object_or_process_affected: "Cell therapy in-lab processing workflows, including biological-safety-cabinet-based manipulation and older lab technologies."
  standard_or_expected_condition: "Unknown; no quantified capacity, utilization, staffing, or backlog standard is provided."
  actual_condition: "Requests for processing are increasing; about 30% of products need in-lab manipulation; they support about 100 clinical trials and 12 or 13 approved commercial cell therapies with more coming; they rely on older technology; BSC-based lab work is said not to keep up."
  source_refs:
    - transcript_id: "IDI01"
      location: "md:line:0027"
      evidence_quote: "requests more and more for processing"
    - transcript_id: "IDI01"
      location: "md:line:0028"
      evidence_quote: "30% of our products need some in la- in-lab manipulation"
    - transcript_id: "IDI01"
      location: "md:line:0073"
      evidence_quote: "about 100 clinical trials"
    - transcript_id: "IDI01"
      location: "md:line:0150"
      evidence_quote: "we do rely on older technology"
    - transcript_id: "IDI01"
      location: "md:line:0169"
      evidence_quote: "12 or 13 approved commercial cell therapies"
    - transcript_id: "IDI01"
      location: "md:line:0169"
      evidence_quote: "more and more coming out"
    - transcript_id: "IDI01"
      location: "md:line:0186"
      evidence_quote: "not gonna be able to keep up"
  derived_from:
    - "IDI01.CONC001"
  confidence: "High"
  notes: null

is_is_not_analysis:
  - dimension: "What"
    is: "The problem is a scalability risk in cell therapy processing workflows: increasing requests and product growth are being handled through in-lab manipulation and lab/BSC-based processing that is stated not to keep up."
    is_not: "In vivo therapies handled by pharmacy are not the affected work described for this group."
    distinctions:
      - "The concern is about processing requests and in-lab manipulation, not all therapy handling."
      - "The affected work is lab/BSC-based processing."
    changes:
      - "Requests for processing are increasing."
    anomalies: []
    supporting_atom_ids:
      - "IDI01.OA001"
      - "IDI01.OA002"
      - "IDI01.OA003"
      - "IDI01.OA004"
      - "IDI01.OA052"
    source_refs:
      - transcript_id: "IDI01"
        location: "md:line:0027"
        evidence_quote: "requests more and more for processing"
      - transcript_id: "IDI01"
        location: "md:line:0028"
        evidence_quote: "30% of our products need some in la- in-lab manipulation"
      - transcript_id: "IDI01"
        location: "md:line:0031"
        evidence_quote: "do not handle any in vivo therapies"
      - transcript_id: "IDI01"
        location: "md:line:0031"
        evidence_quote: "handled by the pharmacy department"
      - transcript_id: "IDI01"
        location: "md:line:0186"
        evidence_quote: "not gonna be able to keep up"
    confidence: "High"

  - dimension: "Where"
    is: "In the cell therapy lab/in-lab manipulation workflow, using older lab technology and biological safety cabinets."
    is_not: "Unknown"
    distinctions:
      - "About 30% of products require in-lab manipulation."
      - "The workflow relies on older lab technology."
    changes: []
    anomalies: []
    supporting_atom_ids:
      - "IDI01.OA002"
      - "IDI01.OA048"
      - "IDI01.OA052"
    source_refs:
      - transcript_id: "IDI01"
        location: "md:line:0028"
        evidence_quote: "30% of our products need some in la- in-lab manipulation"
      - transcript_id: "IDI01"
        location: "md:line:0150"
        evidence_quote: "we do rely on older technology"
      - transcript_id: "IDI01"
        location: "md:line:0150"
        evidence_quote: "water baths"
      - transcript_id: "IDI01"
        location: "md:line:0186"
        evidence_quote: "not gonna be able to keep up"
    confidence: "High"

  - dimension: "When"
    is: "Now and forward-looking: requests are coming more and more, more commercial therapies are coming out, and Catherine says the lab/BSC model is not going to keep up."
    is_not: "Unknown"
    distinctions: []
    changes:
      - "Processing requests are increasing."
      - "More commercial cell therapies are coming out."
    anomalies: []
    supporting_atom_ids:
      - "IDI01.OA001"
      - "IDI01.OA050"
      - "IDI01.OA052"
    source_refs:
      - transcript_id: "IDI01"
        location: "md:line:0027"
        evidence_quote: "requests more and more for processing"
      - transcript_id: "IDI01"
        location: "md:line:0169"
        evidence_quote: "more and more coming out"
      - transcript_id: "IDI01"
        location: "md:line:0186"
        evidence_quote: "not gonna be able to keep up"
    confidence: "High"

  - dimension: "Extent"
    is: "About 30% of products need in-lab manipulation; the organization supports about 100 clinical trials and has about 12 or 13 approved commercial cell therapies, with more therapies coming."
    is_not: "They do not handle any in vivo therapies."
    distinctions:
      - "The affected workload includes a quantified product subset needing lab manipulation."
      - "The portfolio includes about 100 trials and 12 or 13 approved commercial cell therapies."
    changes:
      - "The commercial therapy portfolio is increasing."
    anomalies: []
    supporting_atom_ids:
      - "IDI01.OA002"
      - "IDI01.OA003"
      - "IDI01.OA022"
      - "IDI01.OA049"
      - "IDI01.OA050"
    source_refs:
      - transcript_id: "IDI01"
        location: "md:line:0028"
        evidence_quote: "30% of our products need some in la- in-lab manipulation"
      - transcript_id: "IDI01"
        location: "md:line:0031"
        evidence_quote: "do not handle any in vivo therapies"
      - transcript_id: "IDI01"
        location: "md:line:0073"
        evidence_quote: "about 100 clinical trials"
      - transcript_id: "IDI01"
        location: "md:line:0169"
        evidence_quote: "12 or 13 approved commercial cell therapies"
      - transcript_id: "IDI01"
        location: "md:line:0169"
        evidence_quote: "more and more coming out"
    confidence: "Medium"

possible_causes:
  - id: "IDI01.CAUSE001"
    local_id: "CAUSE001"
    transcript_id: "IDI01"
    corpus_id: "WHALE_HUNT"
    run_id: "RUN_FIRST_LIVE_IDI01_XHIGH_FOUNDATION"
    problem_analysis_id: "IDI01.KTP001"
    selected_concern_id: "IDI01.CONC001"
    cause_statement: "Rising processing demand and an expanding therapy portfolio are a possible cause of capacity pressure."
    cause_type: "change"
    supporting_atom_ids:
      - "IDI01.OA001"
      - "IDI01.OA022"
      - "IDI01.OA049"
      - "IDI01.OA050"
    supporting_evidence:
      - "Processing requests are described as increasing."
      - "The organization supports about 100 clinical trials and has 12 or 13 approved commercial cell therapies."
      - "More commercial cell therapies are coming out."
    contradicting_evidence: []
    explains_is:
      - "Matches the When change evidence that requests and therapies are increasing."
      - "Helps explain why the same lab-based workflows face greater workload exposure."
    explains_is_not:
      - "Unknown"
    source_refs:
      - transcript_id: "IDI01"
        location: "md:line:0027"
        evidence_quote: "requests more and more for processing"
      - transcript_id: "IDI01"
        location: "md:line:0073"
        evidence_quote: "about 100 clinical trials"
      - transcript_id: "IDI01"
        location: "md:line:0169"
        evidence_quote: "12 or 13 approved commercial cell therapies"
      - transcript_id: "IDI01"
        location: "md:line:0169"
        evidence_quote: "more and more coming out"
    derived_from:
      - "IDI01.CONC001"
      - "IDI01.OA001"
      - "IDI01.OA022"
      - "IDI01.OA049"
      - "IDI01.OA050"
    plausibility: "High"
    confidence: "High"
    notes: null

  - id: "IDI01.CAUSE002"
    local_id: "CAUSE002"
    transcript_id: "IDI01"
    corpus_id: "WHALE_HUNT"
    run_id: "RUN_FIRST_LIVE_IDI01_XHIGH_FOUNDATION"
    problem_analysis_id: "IDI01.KTP001"
    selected_concern_id: "IDI01.CONC001"
    cause_statement: "The product mix routes a substantial minority of products into lab manipulation because about 30% need in-lab manipulation."
    cause_type: "distinction"
    supporting_atom_ids:
      - "IDI01.OA002"
    supporting_evidence:
      - "About 30% of products need some in-lab manipulation."
    contradicting_evidence: []
    explains_is:
      - "Explains why the affected object is the in-lab processing workflow rather than only administration."
      - "Explains part of the Extent evidence by identifying the share of products requiring lab work."
    explains_is_not:
      - "Unknown"
    source_refs:
      - transcript_id: "IDI01"
        location: "md:line:0028"
        evidence_quote: "30% of our products need some in la- in-lab manipulation"
    derived_from:
      - "IDI01.CONC001"
      - "IDI01.OA002"
    plausibility: "Medium"
    confidence: "High"
    notes: null

  - id: "IDI01.CAUSE003"
    local_id: "CAUSE003"
    transcript_id: "IDI01"
    corpus_id: "WHALE_HUNT"
    run_id: "RUN_FIRST_LIVE_IDI01_XHIGH_FOUNDATION"
    problem_analysis_id: "IDI01.KTP001"
    selected_concern_id: "IDI01.CONC001"
    cause_statement: "Reliance on older lab technology and BSC-centered processing is a plausible capability constraint on workflow scalability."
    cause_type: "capability_gap"
    supporting_atom_ids:
      - "IDI01.OA048"
      - "IDI01.OA052"
    supporting_evidence:
      - "They rely on older technology such as water baths, biological safety cabinets, and liquid nitrogen Dewars."
      - "Doing everything in a lab with biological safety cabinets is recorded as not able to keep up."
    contradicting_evidence: []
    explains_is:
      - "Directly explains why the stressed object is the lab/BSC-based processing workflow."
      - "Directly accounts for the stated deviation that the current lab model is not going to keep up."
    explains_is_not:
      - "Unknown"
    source_refs:
      - transcript_id: "IDI01"
        location: "md:line:0150"
        evidence_quote: "we do rely on older technology"
      - transcript_id: "IDI01"
        location: "md:line:0150"
        evidence_quote: "water baths"
      - transcript_id: "IDI01"
        location: "md:line:0186"
        evidence_quote: "not gonna be able to keep up"
    derived_from:
      - "IDI01.CONC001"
      - "IDI01.OA048"
      - "IDI01.OA052"
    plausibility: "High"
    confidence: "High"
    notes: null

  - id: "IDI01.CAUSE004"
    local_id: "CAUSE004"
    transcript_id: "IDI01"
    corpus_id: "WHALE_HUNT"
    run_id: "RUN_FIRST_LIVE_IDI01_XHIGH_FOUNDATION"
    problem_analysis_id: "IDI01.KTP001"
    selected_concern_id: "IDI01.CONC001"
    cause_statement: "Multi-container product formats create repeated thawing, testing, transfer, and administration steps that increase workload per product."
    cause_type: "environmental_condition"
    supporting_atom_ids:
      - "IDI01.OA006"
      - "IDI01.OA007"
      - "IDI01.OA008"
      - "IDI01.OA009"
      - "IDI01.OA011"
      - "IDI01.OA012"
      - "IDI01.OA018"
      - "IDI01.OA019"
      - "IDI01.OA020"
      - "IDI01.OA051"
    supporting_evidence:
      - "Some commercial products come in multiple bags, including four, five, or six bags."
      - "Those bags have to be thawed independently and have wait time in between."
      - "A multi-bag product can take three hours for staff and nursing staff to administer."
      - "A product can come in 18 individual vials, each requiring thawing and Gram stain."
      - "Some commercial therapies still use multiple-bag infusions because the big clinical trial was performed that way."
    contradicting_evidence: []
    explains_is:
      - "Increases time and handling burden per case, reducing effective throughput under rising processing requests."
      - "Connects related handling-complexity evidence to the selected concern's lab workflow scalability risk without treating the related concern as the selected problem."
    explains_is_not:
      - "Unknown"
    source_refs:
      - transcript_id: "IDI01"
        location: "md:line:0035"
        evidence_quote: "multiple bags, four, five, six bags"
      - transcript_id: "IDI01"
        location: "md:line:0035"
        evidence_quote: "have to be thawed independently"
      - transcript_id: "IDI01"
        location: "md:line:0035"
        evidence_quote: "have a wait time in between"
      - transcript_id: "IDI01"
        location: "md:line:0036"
        evidence_quote: "take three hours for my staff and the nursing staff to administer that product"
      - transcript_id: "IDI01"
        location: "md:line:0051"
        evidence_quote: "need to be thawed in two or three vials"
      - transcript_id: "IDI01"
        location: "md:line:0051"
        evidence_quote: "placed into a syringe"
      - transcript_id: "IDI01"
        location: "md:line:0061"
        evidence_quote: "18 individual vials"
      - transcript_id: "IDI01"
        location: "md:line:0061"
        evidence_quote: "have to be thawed"
      - transcript_id: "IDI01"
        location: "md:line:0061"
        evidence_quote: "Gram stain performed"
      - transcript_id: "IDI01"
        location: "md:line:0170"
        evidence_quote: "that was how the big clinical trial was performed"
    derived_from:
      - "IDI01.CONC001"
      - "IDI01.CONC002"
      - "IDI01.OA006"
      - "IDI01.OA007"
      - "IDI01.OA008"
      - "IDI01.OA009"
      - "IDI01.OA011"
      - "IDI01.OA012"
      - "IDI01.OA018"
      - "IDI01.OA019"
      - "IDI01.OA020"
      - "IDI01.OA051"
    plausibility: "Medium"
    confidence: "Medium"
    notes: null

  - id: "IDI01.CAUSE005"
    local_id: "CAUSE005"
    transcript_id: "IDI01"
    corpus_id: "WHALE_HUNT"
    run_id: "RUN_FIRST_LIVE_IDI01_XHIGH_FOUNDATION"
    problem_analysis_id: "IDI01.KTP001"
    selected_concern_id: "IDI01.CONC001"
    cause_statement: "Short post-thaw expiration windows and physical distance between lab and patient areas reduce scheduling margin for lab-based processing."
    cause_type: "environmental_condition"
    supporting_atom_ids:
      - "IDI01.OA010"
      - "IDI01.OA013"
      - "IDI01.OA014"
      - "IDI01.OA021"
      - "IDI01.OA040"
    supporting_evidence:
      - "Some products have a post-thaw expiration of 30 minutes or less."
      - "Some products must get to the patient within 30 minutes, and one product must get into the patient in the OR within four hours."
      - "An hour expiration is not enough in some circumstances."
      - "The lab is a 15-minute walk across campus."
    contradicting_evidence: []
    explains_is:
      - "Tight timing margins reduce flexibility in the lab workflow as demand rises."
      - "Helps explain why products requiring in-lab manipulation can stress the workflow when paired with increasing requests."
    explains_is_not:
      - "Unknown"
    source_refs:
      - transcript_id: "IDI01"
        location: "md:line:0051"
        evidence_quote: "30 minutes or less"
      - transcript_id: "IDI01"
        location: "md:line:0051"
        evidence_quote: "get in the patient within 30 minutes"
      - transcript_id: "IDI01"
        location: "md:line:0053"
        evidence_quote: "even an hour expiration really is not enough in some circumstances"
      - transcript_id: "IDI01"
        location: "md:line:0067"
        evidence_quote: "within four hours"
      - transcript_id: "IDI01"
        location: "md:line:0107"
        evidence_quote: "15-minute walk across campus"
    derived_from:
      - "IDI01.CONC001"
      - "IDI01.CONC003"
      - "IDI01.OA010"
      - "IDI01.OA013"
      - "IDI01.OA014"
      - "IDI01.OA021"
      - "IDI01.OA040"
    plausibility: "Medium"
    confidence: "Medium"
    notes: null

most_plausible_cause:
  selected_cause_id: "IDI01.CAUSE003"
  rationale: "IDI01.CAUSE003 is most plausible because it directly matches the selected concern's affected object: lab/BSC-based processing workflows. The same evidence states reliance on older technology and that doing everything in a lab with biological safety cabinets is not going to keep up. Demand growth, in-lab product mix, multi-container formats, and short timing windows explain pressure on the workflow, but IDI01.CAUSE003 best explains why the workflow itself may fail to scale."
  critical_missing_evidence:
    - "Measured current processing capacity, biological safety cabinet utilization, staffing load, and backlog."
    - "Time trend for processing requests and commercial therapy starts, separated by products requiring in-lab manipulation."
    - "Cycle-time and labor-time data for in-lab manipulation, multi-container handling, and short-expiration products."
  confidence: "Medium"

rejected_candidates:
  - cause_statement: "Staff shortages are the cause of the capacity risk."
    related_ids:
      - "IDI01.CONC001"
      - "IDI01.GAP001"
    rejection_reason: "Unsupported; the upstream appraisal identifies capacity, utilization, staffing load, and backlog as unquantified, and no atom states a staffing shortage."
  - cause_statement: "In vivo therapy workload is driving the lab processing capacity risk."
    related_ids:
      - "IDI01.OA003"
      - "IDI01.OA004"
    rejection_reason: "Contradicted; the atoms state they do not handle any in vivo therapies and that pharmacy handles them."
  - cause_statement: "A preferred single ready-to-thaw bag or vial is the cause."
    related_ids:
      - "IDI01.OA005"
    rejection_reason: "Solution-shaped preferred future state, not a cause; the evidence-supported underlying workload issue is represented through product-handling complexity."

verification:
  schema_valid: true
  id_format_valid: true
  required_fields_complete: true
  source_refs_present: true
  derived_from_refs_valid: true
  downstream_ready: true
  transcript_id_prefix_applied: true
  selected_concern_matched: true
  branch_scope_valid: true
  is_is_not_review_complete: true
  no_solution_review_complete: true
  cause_symptom_review_complete: true
  warnings: []
```
